Clinical Trial · NCT04041882

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

Overview

Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the primary tumor and metastatic lesions of neuroendocrine tumors with higher accuracy. This prospective study is going to investigate whether radiolabeled somatostatin analogs 68Ga-DOTATATE PET/CT may be valuable for diagnosis, risk stratification, and prognostic evaluation of neuroendocrine tumors and compared it with 18F-FDG PET/CT.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Zhaohui Zhu, MD,PhD (CONTACT)

zhuzhh@pumch.cn

+86-10-69154196

Zhaohui Zhu, MD,PhD (STUDY_CHAIR)

ClinicalTrials.gov

NCT04041882

Drug / Compound

DOTATATE

Isotope(s):

Target(s):

SSTR2

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

suspected or confirmed untreated NET patients previously performed 18F-FDG PET/CT signed written consent.

Exclusion

pregnancy breastfeeding known allergy against TATE any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.